Why BridgeBio Pharma Inc (BBIO) Stock Is Rising
As of 2026-09-01, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 104.93%. Featured in our EPS revision report on 2026-07-09.
Why BBIO Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised BridgeBio Pharma Inc's next-year EPS growth estimate from 101.88% to 104.56% on 2026-08-28.
- +Sustained Upward Momentum: The estimate has risen consistently across 2 trading sessions since detection, now up a net +0.37 pp to 104.93%.
- ·Current-Year Growth: Projected at 28.57%, supporting the forward estimate revision.
News Context
The primary driver is the upward revision to next-year EPS growth estimates, now at 104.93% after rising from 101.88% on August 28. The revision plausibly connects to positive acoramidis data showing reversal of cardiac structural disease and reduced hospitalizations in ATTR-CM, plus the announced ASCEND-ATTR trial. Since detection, the estimate has continued rising across two trading sessions, indicating sustained momentum. No other near-term headline clearly explains the move.
Generated 2026-09-01 · news as of 2026-09-01
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 104.93%
- EPS growth this year
- 28.57%
- EPS next quarter (est)
- -$0.61
- Last price
- $76.59
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-01 | 104.93% | 28.57% | -$0.61 | $76.59 |
| 2026-08-31 | 104.93% | 28.57% | -$0.61 | $76.59 |
| 2026-08-30 | 104.57% | 29.32% | -$0.61 | $76.60 |
| 2026-08-29 | 104.56% | 29.32% | -$0.62 | $76.60 |
| 2026-08-28 | 104.56% | 29.32% | -$0.62 | $76.60 |
| 2026-08-27 | 101.88% | 29.32% | -$0.62 | $78.68 |
| 2026-08-26 | 101.88% | 29.32% | -$0.62 | $79.37 |
| 2026-08-25 | 101.88% | 29.32% | -$0.62 | $80.40 |
| 2026-08-24 | 101.88% | 29.32% | -$0.62 | $81.07 |
| 2026-08-23 | 101.88% | 29.32% | -$0.62 | $81.50 |
| 2026-08-21 | 101.88% | 29.32% | -$0.62 | $81.50 |
| 2026-08-20 | 101.88% | 29.32% | -$0.62 | $82.94 |
| 2026-08-19 | 101.88% | 29.32% | -$0.62 | $83.95 |
| 2026-08-18 | 101.88% | 29.32% | -$0.62 | $82.98 |
| 2026-08-17 | 101.88% | 29.32% | -$0.62 | $79.89 |
| 2026-08-16 | 101.88% | 29.32% | -$0.62 | $79.86 |
| 2026-08-14 | 101.88% | 29.32% | -$0.62 | $79.86 |
| 2026-08-13 | 101.88% | 29.32% | -$0.62 | $81.21 |
| 2026-08-12 | 101.88% | 29.32% | -$0.62 | $83.84 |
| 2026-08-11 | 106.69% | 30.96% | -$0.60 | $83.70 |
| 2026-08-10 | 125.98% | 41.04% | -$0.49 | $84.67 |
| 2026-08-09 | 125.98% | 41.04% | -$0.58 | $84.48 |
| 2026-08-07 | 125.98% | 41.04% | -$0.58 | $84.48 |
| 2026-08-06 | 125.98% | 41.04% | -$0.58 | $82.80 |
| 2026-08-05 | 125.98% | 41.04% | -$0.58 | $81.99 |
| 2026-08-04 | 125.98% | 41.04% | -$0.58 | $82.07 |
| 2026-08-03 | 125.98% | 41.04% | -$0.58 | $79.96 |
| 2026-08-02 | 122.64% | 40.44% | -$0.58 | $80.09 |
| 2026-07-31 | 122.64% | 40.44% | -$0.58 | $80.09 |
| 2026-07-30 | 122.64% | 40.44% | -$0.58 | $82.14 |
Reports Featuring BBIO
Recent News
- Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CMGlobeNewswire
- BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CMGlobeNewswire
- Hershey Company Upgraded, Toast, Inc. Downgraded: Updated Rankings on Top Blue-Chip StocksInvestorPlace
- BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026GlobeNewswire
- Exelixis, Valaris, and 3 More Stocks See Action From Activist InvestorsBarrons.com
- BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder BaseGlobeNewswire
- BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing ShareholderGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...GuruFocus.com
- BridgeBio Pharma, Inc. Q2 2026 Earnings Call SummaryMoby
Screen Performance
Aggregate stats across all 2024 tickers our top-EPS-revision screen has flagged over the past 153 days.
- Median return since detection
- +1.8%
- % of tickers in the green
- 54%
- Median return on winners
- +20.3%
- Large revisions captured
- 1641
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did BridgeBio Pharma Inc (BBIO) stock go up recently?▾
BridgeBio Pharma Inc (BBIO) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 101.88% to 104.56% on 2026-08-28. The estimate has since risen consistently across 2 additional trading sessions, gaining a net +0.37 pp to 104.93%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-09-01, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 104.93%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-08-31, when analysts adjusted the next-year EPS growth estimate from 104.57% to 104.93%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.